#Hong Kong #Ivonescimab #Pfizer #Summit Therapeutics

Akeso and Partners Progress on Ivonescimab for Cancer Treatment

In an exciting development for cancer treatment, Akeso, Inc. has announced a strategic collaboration with Summit Therapeutics Inc. and Pfizer Inc. to explore the innovative anticancer drug ivonescimab. This clinical trial partnership aims to evaluate the safety and effectiveness of ivonescimab in combination with several antibody-drug conjugates (ADCs) developed by Pfizer, specifically targeting various solid tumors.

Advancing Cancer Treatment

Ivonescimab is a ground-breaking bispecific antibody that targets PD-1 and VEGF, holding the potential to reshape cancer therapy. As noted by Bob Duggan and Dr. Maky Zanganeh, co-CEOs of Summit Therapeutics, the partnership is driven by a commitment to develop novel mechanisms that significantly impact cancer patients who face the most daunting challenges. This collaboration represents an accelerated effort to advance ivonescimab into clinical settings, prioritizing its use in non-small cell lung cancer and other solid tumor types.

The agreement outlines that Summit will supply ivonescimab for the upcoming studies, while Pfizer will manage operational aspects of the clinical trials. Both companies will jointly oversee these studies to ensure comprehensive evaluation and research integrity. Pfizer’s expert oncology team will be integral to the design and execution of these trials, with plans to initiate them mid-year.

Clinical Synergy and Impact

Megan O'Meara, M.D., head of Oncology Early Stage Development at Pfizer, expressed enthusiasm about the collaboration, emphasizing the need to explore rational and differentiated therapeutic combinations. The clinical trials will deploy ivonescimab alongside Pfizer’s ADCs, aiming to address the unique complexities of tumor biology. This innovative approach has the potential to enhance treatment options, providing hope for patients who currently experience unmet medical needs.

Each study will focus on assessing the safety profiles and the potential anti-tumor activities of the combinations, positioning ivonescimab as a crucial component in the fight against cancer.

Background on Ivonescimab

Ivonescimab, also known as SMT112 in certain regions, represents a pioneering achievement in immunotherapy, particularly for EGFR mutated locally advanced or metastatic non-squamous NSCLC patients. Approved by China’s NMPA, it is currently involved in multiple registrational trials that position it against existing anti-PD-1/L1 therapeutics. Akeso is actively engaged in clinical research covering 17 cancer indications, including gastrointestinal cancers, hepatocellular carcinoma, and colorectal cancer, which reaffirms its commitment to addressing a variety of oncological challenges.

The Future of Akeso and Cancer Therapies

Akeso, founded in 2012, is recognized for its robust pipeline and innovative approaches in developing biological medicines. With a focus on integrating research and development into practical treatment methodologies, Akeso operates with over 50 innovative assets across multiple disease domains, aiming to provide affordable and effective treatments worldwide. Its collaboration with prominent partners like Summit Therapeutics and Pfizer underscores its ambition to remain at the forefront of biopharmaceutical advancements.

The upcoming clinical trials reflect a transformative journey in the way cancer therapies can be designed and delivered, with the potential to impact countless lives. As further details emerge regarding these studies, the industry watches closely, hopeful for the breakthroughs that may arise from this significant collaboration.